Clinical Considerations When Introducing Sodium-Glucose Co-Transporter 2 Inhibition in Patients With Heart Failure

Background: In patients with heart failure (HF), discontinued medical therapy because of adverse events (AE) is associated with high mortality. Patients with type 2 diabetes mellitus (T2DM) treated with sodium-glucose co-transporter 2 inhibitors (SGLT2i) have a lower risk of HF, but AE sometimes occ...

Descripción completa

Detalles Bibliográficos
Autores principales: Yazaki, Mayu, Nabeta, Takeru, Inomata, Takayuki, Maemura, Kenji, Ooki, Takumi, Fujita, Teppei, Iida, Yuichiro, Ikeda, Yuki, Ishii, Shunsuke, Naruke, Takashi, Ako, Junya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Circulation Society 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929704/
https://www.ncbi.nlm.nih.gov/pubmed/33693174
http://dx.doi.org/10.1253/circrep.CR-19-0080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929704/
https://www.ncbi.nlm.nih.gov/pubmed/33693174
http://dx.doi.org/10.1253/circrep.CR-19-0080

Ejemplares similares